A phase 2 trial investigating a new drug, ninerafaxstat, showed promising results in improving cardiac function in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). While overall cardiovascular outcomes did not show significant improvement, a post hoc analysis revealed that patients with severe symptoms experienced measurable improvements in heart failure symptoms and exercise capacity. This suggests potential benefit for a subset of nHCM patients. Additionally, the drug was found to be well-tolerated with no significant adverse events. The study demonstrated that ninerafaxstat works by enhancing cardiac efficiency through altering energy utilization. Further investigation into the drug’s efficacy is warranted based on these positive initial results.
Source link
Novel Drug Shows a Signal to Improve nHCM
